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Diabetic neuropathy is associated with increased morbidity and
mortality. To date, limited data in subjects with impaired glucose
tolerance and diabetes demonstrate nerve ﬁber repair after
intervention. This may reﬂect a lack of efﬁcacy of the interven-
tions but may also reﬂect difﬁculty of the tests currently deployed
to adequately assess nerve ﬁber repair, particularly in short-term
studies. Corneal confocal microscopy (CCM) represents a novel
noninvasive means to quantify nerve ﬁber damage and repair.
Fifteen type 1 diabetic patients undergoing simultaneous pan-
creas–kidney transplantation (SPK) underwent detailed assess-
ment of neurologic deﬁcits, quantitative sensory testing (QST),
electrophysiology, skin biopsy, corneal sensitivity, and CCM at
baseline and at 6 and 12 months after successful SPK. At baseline,
diabetic patients had a signiﬁcant neuropathy compared with
control subjects. After successful SPK there was no signiﬁcant
change in neurologic impairment, neurophysiology, QST, corneal
sensitivity, and intraepidermal nerve ﬁber density (IENFD). How-
ever, CCM demonstrated signiﬁcant improvements in corneal
nerve ﬁber density, branch density, and length at 12 months. Nor-
malization of glycemia after SPK shows no signiﬁcant improve-
ment in neuropathy assessed by the neurologic deﬁcits, QST,
electrophysiology, and IENFD. However, CCM shows a signiﬁcant
improvement in nerve morphology, providing a novel noninvasive
means to establish early nerve repair that is missed by currently
advocated assessment techniques. Diabetes 62:254–260, 2013
Diabetic polyneuropathy is one of the mostcommon long-term complications of diabetesand underlies the development of painful neu-ropathy in 21% of both type 1 and type 2 di-
abetic patients (1). It is the main initiating factor for foot
ulceration and lower extremity amputation (2). At present
we have no treatment to repair nerve ﬁbers and improve
diabetic neuropathy. Even in the Diabetes Control and
Complications Trial (DCCT) and follow-up Epidemiology
of Diabetes Interventions and Complications (EDIC)
study, improved glycemic control only delayed the pro-
gression of clinical diabetic neuropathy and indeed nerve
conduction studies at closeout showed no signiﬁcant risk
reduction (3). Furthermore, the Steno-2 study demon-
strated that although multifactorial intervention showed
an improvement in retinopathy, nephropathy, and cardiac
autonomic neuropathy, there was no beneﬁt for somatic
neuropathy (4). Even in the most dramatic example of
“curing” type 1 diabetes with pancreas transplantation, in
115 patients followed over 10 years, neurologic function,
nerve conduction studies, and autonomic function were
only prevented from worsening and failed to show an im-
provement (5). This is in keeping with the lack of im-
provement in heart rate variability, 43 months after
simultaneous pancreas–kidney transplantation (SPK) (6)
and intraepidermal nerve ﬁber density (IENFD) 2.5 years
after SPK (7). Neuropathy is of course extremely severe at
this stage, as evidenced by severe intraepidermal nerve
ﬁber depletion in pancreas transplant recipients, suggest-
ing either a point of no return or the need for long-term
follow-up to identify posttransplant nerve ﬁber regen-
eration (8). However, IENFD and corneal nerve morphol-
ogy have been shown to improve in subjects with impaired
glucose tolerance neuropathy (9) and in patients with type
2 diabetes (10), respectively, after improvement in meta-
bolic risk factors.
To establish efﬁcacy of a new treatment, ideally an im-
provement in diabetic neuropathy has to be shown. Al-
though current end points have a good ability to diagnose
diabetic neuropathy (11), their ability to deﬁne a thera-
peutic response may have signiﬁcant limitations (12). This
may indeed be a major reason why clinical trials in human
diabetic neuropathy have failed to reach prespeciﬁed pri-
mary end points such as neuropathic deﬁcits and electro-
physiology (13). The assessments of neurologic symptoms
and deﬁcits have recently been shown to have poor di-
agnostic reproducibility (14). Although electrophysiology
correlates with large ﬁber damage, it does not assess small
ﬁbers, which are the earliest to be damaged (15) and dem-
onstrate repair even in advanced neuropathy (12). Nerve ﬁ-
ber morphology in sural nerve biopsies (16) and IENFD in
skin-punch biopsies (17) can accurately quantify nerve ﬁber
damage and repair, but both are invasive procedures.
We and others (18,19) have used corneal confocal mi-
croscopy (CCM) to detect subclinical diabetic neuropathy
and relate it to the severity of somatic neuropathy (20) and
IENFD (21) with good sensitivity and speciﬁcity (20). This
led us to propose that CCM, a noninvasive and reiterative
test, might be an ideal surrogate end point for evaluating
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therapeutic efﬁcacy in clinical trials of human diabetic
neuropathy (22). In a preliminary study, we have pre-
viously shown a signiﬁcant improvement in corneal nerve
ﬁber density (CNFD) and length 6 months after SPK (23),
but at that time we did not compare CCM with established
end points of diabetic neuropathy. In the current study we
have compared CCM with neurologic deﬁcits, quantitative
sensory testing (QST), electrophysiology, and IENFD at
baseline and 6 and 12 months after SPK to help deﬁne the
measures that may best detect an improvement in diabetic
neuropathy after intervention.
RESEARCH DESIGN AND METHODS
Selection of patients. Fifteen type 1 diabetic patients were evaluated at
baseline and 6 and 12 months after SPK and compared with 10 age/sex-matched
nondiabetic healthy control subjects. The healthy volunteers were recruited
from the general population. Both patients and control subjects underwent full
neurologic and medical assessments. Those patients with any history of sys-
temic (apart from diabetes for patient group) or neurologic conditions or
history of ocular trauma and those wearing contact lens or those who have had
ocular surgery were excluded. The study was approved by the Central Man-
chester Ethics Committee, and written informed consent was obtained
according to the Declaration of Helsinki.
Assessment of neuropathy. All patients and control subjects underwent
a detailed evaluation of neurologic symptoms according to the neuropathy
symptom proﬁle (NSP), and theMcGill pain analog score was used to assess the
severity of painful neuropathy. Neurologic deﬁcits were assessed using the
modiﬁed neuropathy disability score (NDS), which includes evaluation of vi-
bration, pin prick, and temperature perception as well as the presence or
absence of ankle reﬂexes to establish the severity of neuropathy: NDS 0–2, no
neuropathy; NDS 3–5, mild neuropathy; NDS 6–8, moderate neuropathy; and
NDS 9–10, severe neuropathy. Quantitative sensory testing included an as-
sessment of vibration perception threshold (VPT), measured on the ﬁrst toe
using a Neurothesiometer (Horwell, Scientiﬁc Laboratory Supplies, Wilford,
Nottingham, U.K.), cold sensation (CS) (Ad ﬁbers) and warm sensation (WS)
(C ﬁbers) thresholds using the method of limits with the MEDOC TSA II
(Medoc, Ramat Yishai, Israel) on the dorsum of the left foot (24).
Computer-Aided Sensory Evaluator (CASE IV) was used tomeasure the heart
rate response to deep breathing. In this test, the patient was asked to inhale and
exhale deeply eight times in a row in the supine position while following the
rhythm of a “breathing cue,” and the changes in heart rate were displayed on an
ECG monitor. Two eight-cycle breathing series’were completed interspersed by
a 5-min period of normal breathing. The acquired data were analyzed by cal-
culating the mean difference between the highest and lowest heart rate for ﬁve
consecutive, artifact-free cycles in each eight-cycle series.
Electro-diagnostic studies were undertaken using a Dantec “Keypoint”
system (Dantec Dynamics, Bristol, U.K.) equipped with a Dansk Industri
Syndikat temperature regulator to keep limb temperature constantly between
32°C and 35°C. Peroneal motor and sural sensory nerves were assessed in the
right lower limb by a consultant neurophysiologist. The motor study was
performed using silver-silver chloride surface electrodes at standardized sites
deﬁned by anatomical landmarks, and recordings for the sural nerve were
taken using antidromic stimulation over a distance of 100 mm.
Corneal sensitivity. Corneal sensitivity was quantiﬁed using a noncontact
corneal aesthesiometer (NCCA) (Glasgow Caledonian University, Glasgow,
Scotland, U.K.), which uses a puff of air through a bore 0.5 mm in diameter
lasting 0.9 s and exerting a force expressed in millibars (mbars) (25). The
stimulus jet is mounted on a slit lamp and is positioned 1 cm from the eye, and
the air jet is aligned to the center of the cornea. Each subject was presented
with a supramaximal stimulus, and the staircase method was used by reducing
the stimulus strength until the patient did not feel the jet on three occasions, to
establish the threshold. The coefﬁcient of variation for NCCA was 5.6%.
CCM. Patients underwent examination with the Heidelberg retina tomograph
III in vivo corneal confocal microscope. The subject’s eyes were anesthetized
using a drop of 0.4% benoxinate hydrochloride, and Viscotears were applied
on the front of the eye for lubrication. A drop of viscoelastic gel was placed on
the tip of the objective lens, and a sterile disposable Perspex cap was placed
over the lens allowing optical coupling of the objective lens to the cornea. The
patient was instructed to ﬁxate on a target with the eye not being examined.
Several scans of the entire depth of the cornea were recorded by turning the
ﬁne focus of the objective lens backward and forward for ~2 min using the
section mode, which enables manual acquisition and storage of single images
of all corneal layers. This provides en face two-dimensional images with
a lateral resolution of ~2 mm/pixel and ﬁnal image size of 400 3 400 pixels of
the subbasal nerve plexus of the cornea from each patient and control subject.
This layer is of particular relevance for deﬁning neuropathic changes since it is
the location of the main nerve plexus that supplies the overlying corneal ep-
ithelium. Each nerve ﬁber bundle contains unmyelinated ﬁbers, which run
parallel to Bowman’s layer before dividing and terminating as individual axons
underneath the surface epithelium (26). Five images per patient from the
center of the cornea were selected and examined in a masked and randomized
fashion (27). Three corneal nerve parameters were quantiﬁed: 1) CNFD, the
total number of major nerves per square millimeter of corneal tissue; 2) cor-
neal nerve branch density (CNBD), the number of branches emanating from
all major nerve trunks per square millimeter of corneal tissue; and 3) corneal
nerve ﬁber length (CNFL), the total length of all nerve ﬁbers and branches
(mm/mm2) within the area of corneal tissue. CNFD and CNFL are considered
to reﬂect overall nerve ﬁber degeneration, whereas CNBD reﬂects nerve ﬁber
regeneration, which is partially also captured by CNFL.
Skin biopsy and immunohistochemistry. A 3-mm punch skin biopsy was
taken from the dorsum of the foot ;2 cm above the second metatarsal head
after local anesthesia (1% lidocaine). The biopsy site was closed using Steri-
strips, and the specimen was immediately ﬁxed in PBS-buffered 4% para-
formaldehyde. After 18–24 h, it was rinsed in Tris-buffered saline and soaked
in 33% sucrose (2–4 h) for cryoprotection. It was then embedded in optimal
cutting temperature–embedding compound, rapidly frozen in liquid nitrogen,
and cut into 50-mm sections using a cryostat (model OTF; Bright Instruments,
Huntington, U.K.). Four ﬂoating sections per subject were subjected to mel-
anin bleaching (0.25% KMnO4 for 15 min followed by 5% oxalic acid for 3 min),
a 4-h protein block with a Tris-buffered saline solution of 5% normal swine
serum, 0.5% powdered milk, and 1% Triton X-100, and overnight incubation
with 1:1,200 Biogenesis polyclonal rabbit anti-human PGP9.5 antibody
(Serotec, Oxford, U.K.). Biotinylated swine anti-rabbit secondary antibody
(1:300; DakoCytomation, Ely, U.K.) was then applied for 1 h; sections were
quenched with 1% H2O2 in 30% MeOH-PBS (30 min) before a 1-h incubation
with 1:500 horseradish peroxidase–streptavidin (Vector Laboratories, Peter-
borough, U.K.). Nerve ﬁbers were demonstrated using 3, 3 ́-diaminobenzidine
chromogen (Sigma-Aldrich, Manchester, U.K.). Sections were mildly coun-
terstained with eosin to better localize the basement membrane to identify
nerve ﬁbers passing through it. Negative control subjects consisted of replacing
the anti-PGP9.5 antibody with rabbit immunoglobulin (DakoCytomation) at
a concentration matching that of the primary antibody, which showed no
immunostaining. IENFD, i.e., the number of ﬁbers per millimeter of basement
membrane, was quantiﬁed in accord with established criteria and techniques
and expressed as number per millimeter (28).
Statistics. SPSS 16.05.0 forWindowswas used to compute the results. Analysis
included descriptive and frequency statistics. All data are expressed as
means 6 SEM. A paired sample t test was used to test whether a sample mean
(of a normally distributed interval variable) differed between control subjects
and diabetic patients at baseline and at follow-up 6 and 12 months after SPK.
RESULTS
The clinical characteristics and detailed assessment of
neuropathy in diabetic patients and age-matched control
subjects are summarized in Table 1. BMI was non-
signiﬁcantly lower in diabetic patients and showed an in-
crease after SPK. HbA1c was higher in diabetic patients
compared with control subjects and improved into the
normal range at 6 and 12 months after SPK, but this was
not statistically signiﬁcant. The total cholesterol was sig-
niﬁcantly lower (P = 0.01) in diabetic patients and
remained the same at 6 and 12 months after SPK. Both
HDL and triglycerides were comparable between diabetic
patients and control subjects, and remained unchanged
after SPK. The estimated glomerular ﬁltration rate was
lower in diabetic patients at baseline (P = 0.02) and did not
change signiﬁcantly at 6 and 12 months after SPK.
Symptoms and neurologic deﬁcits. Neuropathic symp-
toms as assessed with the NSP were signiﬁcantly greater in
diabetic patients than in control subjects at baseline (P =
0.005), but there was no signiﬁcant improvement at 6 (P =
0.1) or 12 (P = 0.9) months after transplantation. The
McGill pain index was signiﬁcantly (P = 0.01) greater at
baseline compared with control subjects and did not show
a signiﬁcant change at 6 (P = 0.9) or 12 (P = 0.9) months
after transplantation. The modiﬁed NDS was signiﬁcantly
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(P = 0.003) greater at baseline compared with control
subjects, indicating a mild to moderate neuropathy, and
did not change signiﬁcantly at 6 (P = 0.7) or 12 (P = 0.8)
months after transplantation (Table 2).
Quantitative sensory tests. VPT was signiﬁcantly
greater in diabetic patients compared with control subjects
at baseline (P = 0.01) and did not change signiﬁcantly at 6
(P = 0.1) or 12 (P = 0.6) months after transplantation. CS
was signiﬁcantly greater in diabetic patients compared
with control subjects at baseline (P = 0.004) and did not
change signiﬁcantly at 6 (P = 0.5) or 12 (P = 0.5) months
after transplantation. WS was signiﬁcantly greater in di-
abetic patients compared with control subjects at baseline
(P = 0.005) and did not change signiﬁcantly at 6 (P = 0.9) or
12 (P = 0.4) months after transplantation.
Autonomic function. Average heart rate variability was
signiﬁcantly lower in diabetic patients compared with
control subjects at baseline (P = 0.01) and did not change
signiﬁcantly at 6 (P = 0.9) or 12 (P = 0.8) months after
SPK.
Electrophysiology. Peroneal nerve conduction velocity
and amplitude were signiﬁcantly lower in diabetic patients
compared with control subjects at baseline (P = 0.0001,
P = 0.0001, respectively) and did not change signiﬁcantly
at 6 (P = 0.6, P = 0.5) or 12 (P = 0.3, P = 0.2) months after
transplantation. Sural nerve conduction velocity and
amplitude were signiﬁcantly lower in diabetic patients
compared with control subjects at baseline (P = 0.003, P =
0.001, respectively) and did not change signiﬁcantly at 6
(P = 0.7, P = 0.9) or 12 (P = 0.6, P = 0.3) months after
transplantation (Table 2).
IENFD. IENFD was signiﬁcantly lower in diabetic patients
compared with control subjects at baseline (P , 0.0001)
and did not show a signiﬁcant improvement 12 months
after transplantation (P = 0.9) (Fig. 1 and Table 3).
Corneal sensation. The corneal sensation threshold was
signiﬁcantly greater in diabetic patients compared with
control subjects at baseline (P = 0.03) and did not change
at 6 (P = 0.9) or 12 (P = 0.9) months after transplantation
(Table 3).
CCM. Representative images from a diabetic patient at
baseline show a marked reduction in subbasal corneal
nerves with a progressive repair at 6 and 12 months after
SPK. CNFD was signiﬁcantly lower in diabetic patients
compared with control subjects at baseline (P , 0.0001),
did not improve at 6 months (P = 0.7), but reached signiﬁ-
cance at 12 months (P = 0.02). Similarly, CNFL was signif-
icantly lower in diabetic patients compared with control
subjects at baseline (P , 0.0001) and did not improve
at 6 months (P = 0.2) but reached statistical signiﬁcance at
TABLE 1
Clinical demographic results in control subjects and type 1 diabetic patients undergoing SPK at baseline and follow-up visits at 6 and
12 months
Parameter Control subjects Baseline
Follow-up
6 months 12 months
n (female/male) 10 (3/7) 15 (5/10) 15 15
Age (years) 47 6 3 47 6 3 — —
Diabetes duration (years) 0 27 6 3.5 — —
BMI (kg/m2) 27 6 1 22 6 2 25.5 6 1 25.5 6 1
HbA1c (%) 5.7 6 0.1 7.4 6 0.8 5.9 6 0.3 5.9 6 0.4
Cholesterol (mmol/L) 5.1 6 0.2 4.0 6 0.3* 4.3 6 0.3 4.5 6 0.3
HDL (mmol/L) 1.5 6 0.1 1.3 6 0.2 1.5 6 0.2 1.6 6 0.2
Triglycerides (mmol/L) 1.3 6 0.2 1.4 6 0.1 1.2 6 0.1 1.03 6 0.1
Estimated glomerular ﬁltration rate (mL/min/L) 86.22 6 2.13 60.53 6 8.64† 64.0 6 7.5 66.0 6 6.19
Data are presented as mean 6 SEM in diabetic patients and control subjects unless otherwise indicated. All symbols represent statistically
signiﬁcant differences using paired sample t test. *P , 0.01. †P , 0.02 (baseline vs. control).
TABLE 2
Clinical neuropathy evaluation in control subjects and type 1 diabetic patients undergoing SPK at baseline and follow-up visits at 6 and
12 months
Parameter Control subjects Baseline
Follow-up
6 months 12 months
NSP (0–38) 0 6.7 6 1.8† 7.6 6 2.2 7.3 6 2.0
NDS (0–10) 0.3 6 0.2 4.6 6 0.9† 5.0 6 1.1 5.4 6 0.7
McGill pain index 0 1.7 6 0.6* 1.9 6 0.8 1.3 6 0.5
VPT (volts) 6.7 6 1.8 19.4 6 3.7* 17.4 6 3.3 16.9 6 3.4
CS (°C) 29.3 6 0.4 17.5 6 3.1† 19.8 6 2.9 20.0 6 2.7
WS (°C) 38.1 6 0.8 43.7 6 1.4† 43.8 6 1.2 42.3 6 1.1
Heart rate variability (average bpm) 15.3 6 2.1 7.1 6 1.7† 5.7 6 1.7 4.9 6 2.1
Sural nerve conduction velocity (m/s) 47.9 6 0.5 40.6 6 2.2† 41.5 6 1.6 41.8 6 1.9
Sural amplitude (mA) 20.7 6 3.4 5.1 6 0.9† 5.1 6 0.9 4.0 6 0.6
Peroneal nerve conduction velocity (m/s) 47.7 6 0.9 35.9 6 1.8‡ 37.7 6 1.2 38.5 6 1.8
Peroneal amplitude (mV) 12.2 6 0.9 2.4 6 0.4‡ 1.9 6 0.4 1.7 6 0.3
Data are presented as mean 6 SEM in diabetic patients and control subjects. All symbols represent statistically signiﬁcant differences using
paired sample t test. *P , 0.05. †P , 0.01. ‡P , 0.001 (baseline vs. control; 6 months vs. baseline; 12 months vs. baseline).
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12 months (P = 0.03). CNBD was signiﬁcantly lower in
diabetic patients compared with control subjects at base-
line (P , 0.0001) but showed a signiﬁcant improvement
(P = 0.03) at 6 months and continued to improve signiﬁ-
cantly (P = 0.008) at 12 months (Figs. 2 and 3).
Although IENFD did not show an improvement at 12
months, it showed a signiﬁcant correlation with corneal
nerve parameters including CNFD (P = 0.656, r , 0.0001),
CNBD (P = 0.709, r , 0.0001), and CNFL (P = 0.695, r ,
0.0001).
DISCUSSION
The natural history of nerve damage in patients with type 1
diabetes is not entirely clear. Longitudinal data from the
Rochester cohort support the contention that the duration
and severity of exposure to hyperglycemia are related to
the progression and hence severity of neuropathy rather
than its onset (29). In type 1 diabetes the development of
diabetic neuropathy has been related not only to glycemic
control but also to conventional cardiovascular risk fac-
tors such as hypertension and lipids (30). The Toronto
consensus identiﬁed clinical and neurophysiologic evalu-
ation combined with quantitative sensory and autonomic
function testing as well as small ﬁber evaluation to di-
agnose neuropathy (11). However, there is no clear con-
sensus as to the critical end points, which should be used
to deﬁne the beneﬁts of therapeutic intervention.
The cure for type 1 diabetes is via pancreas trans-
plantation, which normalizes blood glucose. Over the past
20 years, the survival and mortality of SPK transplants has
improved signiﬁcantly (31); therefore, it provides the ideal
intervention to assess whether the long-term complica-
tions of diabetes are reversible. Some studies show that
retinopathy can deteriorate in 10–35% of patients with
unstable eye disease immediately after pancreas trans-
plantation, but beneﬁts do become apparent after several
years (32,33). Other studies demonstrate an improvement
and/or stabilization of diabetic retinopathy after a median
follow-up of only 17 months (34,35). For nephropathy,
normoglycemia can stop the progression of diabetic glo-
merulopathy, but does not reverse it (36,37). Similarly,
pancreas transplantation alone can limit further reduction
in glomerular ﬁltration rate (33), and SPK protects the
graft kidney from developing diabetic nephropathy (38).
With regard to neuropathy, pancreas transplantation has
previously been shown to improve nerve conduction and
motor and sensory action potentials in the upper but not
the lower limb as well as sudomotor function (5),within 1
year, but with no impact on autonomic function (5–7). SPK
has been shown to improve gastric emptying and symp-
toms related to gastroparesis compared with kidney
transplantation alone (39), although gastrointestinal
symptoms and autonomic deﬁcits do not correlate with
each other. In a recent study in 18 type 1 diabetic patients
there was no improvement in IENFD 21–40 months post-
SPK (7). However, most patients receiving transplantation
had severe nerve ﬁber damage as evidenced by marked
depletion of intraepidermal nerve ﬁbers (8).
Although nerve conduction studies and quantitative
sensory testing are useful and well-validated measures to
help diagnose and assess the progression of diabetic neu-
ropathy, their utility in evaluating a therapeutic response
may be limited (40). More detailed and reproducible
measures, which accurately quantify small ﬁber neuropa-
thy via skin or nerve biopsy, may be more sensitive but are
invasive (15–17). There is now an increasing literature on
the potential for CCM to quantify C-ﬁber pathology in pe-
ripheral neuropathies (18,41,42). Detailed morphometric
and immunohistological studies have demonstrated that
the subbasal nerve ﬁber bundles studied by CCM are
FIG. 1. A: Skin biopsies immunostained for PGP9.5. Healthy control (A)
shows numerous intraepidermal nerve ﬁbers (red arrowheads) reach-
ing upper levels of epidermis with a well-developed subepidermal nerve
plexus (yellow arrowheads) in a healthy subject (A) compared with
scant subepidermal and minimal intraepidermal nerve ﬁbers in
the diabetic patient both at baseline (B) and at follow-up (C). Scale
bar = 100 mm. B: IENFD in control subjects and in diabetic patients at
baseline and 12 months after SPK. Data are mean 6 SEM. (A high-
quality digital representation of this ﬁgure is available in the online
issue.)
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predominantly nociceptive C ﬁbers (43,44). Indeed, CCM
has been applied to evaluate diabetic neuropathy (19,20),
idiopathic small ﬁber neuropathy (45), and Fabry disease
(46).We have shown that corneal nerve damage assessed
using CCM relates to the severity of intraepidermal nerve
ﬁber loss (21) and is related to a loss of corneal sensitivity
(25) in diabetic neuropathy. CCM detects very early small-
ﬁber damage even in subjects with an elevated HbA1c, still
within the normal range (18), and HbA1c levels 7–10 years
before CCM correlate with the severity of nerve damage
(47). Furthermore, an improvement in HbA1c by optimizing
medical therapy (10) and pancreas transplantation (23) led
to corneal nerve regeneration, shown using CCM. How-
ever, in these studies the evaluation of neuropathy was
limited to CCM.
The present study allowed us to evaluate the relative
ability of CCM to detect nerve ﬁber repair compared with
all other established measures for assessing neuropathy,
including neurologic deﬁcits, QST, neurophysiology, and
IENFD. The results demonstrate a severe neuropathy in
diabetic patients before SPK as evidenced by signiﬁcant
abnormalities in electrophysiology, QST, IENFD, and
corneal nerve ﬁbers, conﬁrming previous studies (5–8).
However, despite this considerable baseline damage, we
now show a signiﬁcant improvement in corneal nerve
branch density within 6 months of transplantation. This
improvement conﬁrms our previous work (23) indicating
an early nerve-ﬁber repair process with the restoration of
euglycemia, followed by a signiﬁcant improvement in
nerve-ﬁber density and nerve-ﬁber length 12 months after
SPK. This is in contrast to all other standard measures of
neuropathy, including detailed QST, autonomic function,
electrophysiology, and IENFD, all of which failed to show
an improvement 12 months after SPK. These ﬁndings
support previous studies in diabetic neuropathy where at
best a prevention of progression in nerve damage was
shown only after several years of euglycemia (5–8,48–51).
However, these studies focused heavily on electrophysi-
ology and quantitative sensory assessment, which pre-
dominantly assessed large ﬁber function. It is relevant that
where small ﬁber function was assessed in the form of
sudomotor function, a signiﬁcant improvement was dem-
onstrated within 1 year of SPK (5,7). The main limitations
of this study are the small number of subjects studied, the
TABLE 3
Corneal sensitivity, corneal nerve morphology, and IENFD in control subjects and type 1 diabetic patients at baseline and after SPK at
6 and 12 months
Parameter Control subjects Baseline
Follow-up
6 months 12 months
NCCA (mbars) 0.56 6 0.1 1.78 6 0.42* 1.83 6 0.73 1.84 6 0.89
CNFD (no./mm2) 35.77 6 1.53 14.44 6 1.20‡ 15.22 6 1.63 19.27 6 1.57*
CNBD (no./mm2) 100.92 6 13.1 21.46 6 3.78‡ 36.85 6 6.04* 43.02 6 6.48†
CNFL (mm/mm2) 27.93 6 1.26 11.35 6 1.04‡ 13.35 6 1.50 15.63 6 1.56*
IENFD (no./mm) 9.77 6 1.24 2.03 6 0.61‡ — 2.31 6 1.17
Data are presented as mean 6 SEM in diabetic patients and control subjects. Note that skin biopsy was not performed at 6 months. All
symbols represent statistically signiﬁcant differences using paired sample t test. *P , 0.05. †P , 0.01. ‡P , 0.001 (baseline vs. control; 6
months vs. baseline; 12 months vs. baseline).
FIG. 2. CCM images from Bowman’s layer of cornea: a control subject (A) and patient with type 1 diabetes at baseline (B) and at 6 (C) and 12 (D)
months after SPK. The red arrows indicate main nerve ﬁbers, and yellow arrows indicate branches. (A high-quality color representation of this
ﬁgure is available in the online issue.)
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possibility of false-positive results based on the number of
comparisons, the lack of sudomotor testing given its pre-
vious improvement in these patients, and the lack of
blinding given that all patients were known to have had
a SPK during the follow-up period. Furthermore, with
regard to the lack of improvement in IENFD, this may
reﬂect the location of the skin biopsy as we assessed this
on the dorsum of the foot, whereas a previous study (9)
has shown that proximal IENFD assessment in the thigh is
more responsive to intervention. Similarly, for neuro-
physiological assessment it has been suggested that upper
limb neurophysiology may show a better response to in-
tervention as a result of lesser severity of damage (52).
We now conﬁrm and extend the results of our previous
study using the latest generation Heidelberg retina tomo-
graph III, which provides enhanced small ﬁber imaging
and detects earlier nerve ﬁber repair, particularly reﬂected
in the increase in nerve branch density, followed by sig-
niﬁcant improvements in nerve ﬁber density and length.
We believe these data provide further support for the need
to study small ﬁbers as surrogate markers and end points
in intervention trials of diabetic neuropathy. An important
issue with regard to the utility of CCM or indeed any sur-
rogate end point has to be that these alterations in corneal
nerve morphology predict deterioration of neuropathy and
ultimately clinically meaningful outcomes such as foot
ulceration. An alternative interpretation of this data could
of course be that CCM is measuring something unique that
is not an accurate biomarker of how other peripheral
nerves are faring or indeed that corneal nerves respond
well to restoration of insulin and normoglycemia, whereas
other peripheral nerves do not. Nevertheless, CCM ap-
pears to represent a promising noninvasive and hence re-
iterative test with high sensitivity, which may represent an
ideal surrogate end point for assessing the beneﬁts of
pancreas transplantation and indeed other therapies in
clinical trials of human diabetic neuropathy.
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